Shares of INNOVATE Corp. VATE have gained 5.3% since reporting second-quarter 2026 results, outperforming the S&P 500 index’s 0.5% return. However, over the past month, the stock has declined 14.8%, while the index has advanced 4.1%.
Earnings & Revenue Performance
Second-quarter revenues rose 74.2% to $421.6 million from $242 million in the prior-year quarter. Net income attributable to common stockholders and participating preferred stockholders was $10.4 million, reversing a $22-million loss. At the same time, earnings were 71 cents per share against a loss of $1.67 per share in the prior-year quarter. Total adjusted EBITDA increased 194.9% to $46.3 million from $15.7 million. Gross profit climbed to $79.5 million from $45.6 million, and operating income increased to $34.5 million from $4.9 million.
Other Key Business Metrics
Infrastructure revenues advanced 77.6% to $414 million from $233.1 million, with segment net income rising to $26.4 million from $5.5 million, and adjusted EBITDA to $48.7 million from $19.3 million. The gross margin improved about 60 basis points to 18.5%, while the adjusted EBITDA margin expanded about 350 basis points to 11.8%. As of June 30, reported backlog was $1.9 billion and adjusted backlog, including awarded but unsigned contracts, was $2.7 billion compared with $1.7 billion and $1.8 billion, respectively, as of Dec. 31, 2025.
Life Sciences revenues fell 31.3% to $2.2 million from $3.2 million in the prior-year quarter, though its adjusted EBITDA loss narrowed to $0.8 million from $2.6 million. R2 Technologies generated $3.6 million in demand and ended with 110 systems in backlog, representing $1.4 million in future revenues. Spectrum revenues eased to $5.4 million from $5.7 million, and adjusted EBITDA declined to $0.4 million from $1 million. Excluding restricted and held-for-sale amounts, cash fell to $87.8 million from $108.2 million at the year-end, while total principal debt increased to $626.4 million from $617.5 million.
Management Commentary
Interim CEO Paul Voigt characterized DBM Global’s quarter as record-breaking, citing execution and backlog growth. Management identified data centers, technology, healthcare and New York City as activity drivers, alongside investment in artificial intelligence infrastructure, semiconductors, advanced manufacturing, energy systems and digital connectivity. Voigt said that MediBeacon was engaged with more than 100 healthcare institutions about its TGFR kidney-function system, while R2 was expanding and using lower costs to improve operating leverage.
Factors Influencing Headline Numbers
The revenue increase mainly reflected the timing and scale of large structural-steel projects at DBMG, together with revisions to cost-to-complete estimates arising from project efficiencies. Construction modeling, detailing and the new modular business also contributed, while industrial maintenance and repair activity declined as prior-year projects were completed. Life Sciences was pressured by fewer Glacial fx units in North America and Glacial Spa units internationally because of liquidity constraints. Spectrum was affected by terminated networks and markets, partly offset by launches.
Net income benefited from a $33.9-million increase in gross profit and an $18.7-million year-over-year improvement in gains on debt extinguishment. Those benefits were partly offset by increases of $8.9 million in tax expenses, $6.4 million in selling, general and administrative expenses, and $6.2 million in interest expenses. Higher taxes reflected stronger pretax income and limits on use of net operating losses.
Management Outlook
Management said DBMG’s backlog supports visibility into 2027 and 2028 and pointed to a robust second-half project pipeline, while emphasizing capacity discipline and margin preservation. R2 entered the second half with strong demand but was seeking additional capital for inventory, manufacturing scale-up and commercial expansion. MediBeacon targets a pivotal study of its third-generation wireless TGFR sensor in 2027 and a European Lumitrace marketing-authorization filing that year.
Other Developments
Broadcasting completed a $105-million refinancing used to retire 8.50% and 11.45% notes, repurchase certain equity interests and cover transaction costs. INNOVATE also agreed to sell CONX Corp. an approximately 75% controlling interest in Broadcasting, retaining about 25%, subject to FCC and other approvals. Management said that the refinancing loan is expected to be extinguished at closing and CONX has committed up to $75 million in post-closing equity. INNOVATE continued a sale process for substantially all DBMG assets or equity. After quarter-end, R2 extended a secured-note maturity from Aug. 1 to Dec. 31, 2026, and converted preferred equity to common equity.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
INNOVATE Corp. (VATE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
